Elasmogen Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Elasmogen Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11265
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Elasmogen Ltd (Elasmogen), formerly Pacific Shelf 1760 Ltd is a biopharmaceutical company that discovers and develops sight-saving therapies for the treatment of inflammatory diseases of the eye and inflammatory conditions of the gut. The company develops soloMER that are small (11 kDa) and stable proteins that have squeezed a fourth binding loop into their single domain format and are derived evolutionarily from a non-antibody lineage, placing them outside the complex or competitive antibody patent landscape. Its pipeline includes ELN/21 and ELN/22, which are auto-immune mediated anti-inflammatory programs; soloMER-drug-conjugates; and NDure, a soloMER humanized clinical candidate available for extending the plasma half-life of fused partner molecules, such as scFv, peptides, growth factors, single domains, and others. Elasmogen is headquartered in Aberdeen, the UK.

Elasmogen Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Elasmogen Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Elasmogen Raises Funds through Equity Financing 10
Partnerships 11
Elasmogen, Feldan Bio Enter into Agreement with Amgen 11
Feldan Bio and Elasmogen Enter into Development Partnership 12
Elasmogen and Almac Discovery Enter into Co-Development Agreement 13
Equity Offering 14
Elasmogen Spin Off from University of Aberdeen 14
Elasmogen Ltd – Key Competitors 15
Elasmogen Ltd – Key Employees 16
Elasmogen Ltd – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Government and Public Interest 18
Aug 06, 2018: Almac discovery, Elasmogen and Innovate UK collaborate to develop VNAR based oncology platform 18
Mar 16, 2017: Elasmogen Receives £1.2 M In Grant And Equity Investment 19
Product News 20
Jan 20, 2017: Elasmogen – shark proteins for drug discovery 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Elasmogen Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Elasmogen Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Elasmogen Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Elasmogen Raises Funds through Equity Financing 10
Elasmogen, Feldan Bio Enter into Agreement with Amgen 11
Feldan Bio and Elasmogen Enter into Development Partnership 12
Elasmogen and Almac Discovery Enter into Co-Development Agreement 13
Elasmogen Spin Off from University of Aberdeen 14
Elasmogen Ltd, Key Competitors 15
Elasmogen Ltd, Key Employees 16

List of Figures
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Elasmogen Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Elasmogen Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • China Resources Power Holdings Co Ltd:発電所・企業SWOT分析
    China Resources Power Holdings Co Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informatio …
  • MAXrad SOFTware (India) Pvt. Ltd.:企業の戦略・SWOT・財務情報
    MAXrad SOFTware (India) Pvt. Ltd. - Strategy, SWOT and Corporate Finance Report Summary MAXrad SOFTware (India) Pvt. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • CEL-SCI Corp (CVM):製薬・医療:M&Aディール及び事業提携情報
    Summary CEL-SCI Corp (CEL-SCI) is a biotechnology company that carries out the research and development of new immunotherapy products for the treatment of various cancer and infectious diseases. Its core capabilities include drug discovery, research, development and manufacturing of compound biologi …
  • Medicenna Therapeutics Corp (MDNA):製薬・医療:M&Aディール及び事業提携情報
    Summary Medicenna Therapeutics Corp (Medicenna), formerly A2 Acquisition Corp, is a clinical stage immuno-oncology company. The company develops empowered cytokines (EC) and superkines for the treatment of cancer. Its pipeline products include MDNA55, MDNA109, MDNA209, MDNA57, MDNA413, and MDNA132. …
  • Golden Agri-Resources Ltd:企業の戦略・SWOT・財務情報
    Golden Agri-Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Golden Agri-Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • UTC Engenharia SA:企業の戦略的SWOT分析
    UTC Engenharia SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Mologic Ltd:企業の製品パイプライン分析2018
    Summary Mologic Ltd (Mologic) is a medical device company that designs, develops, manufactures and markets in vitro diagnostic medical devices. The company provides products such as bacterial vaginosis test kit, peritoneal dialysis test, lateral flow kit, desmosine ELISA kit and FMLP ELISA kit, amon …
  • Atnahs Pharma UK Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Atnahs Pharma UK Ltd (Atnahs Pharma), a subsidiary of Waymade Plc, is a developer, manufacturer, supplier and distributor of pharmaceutical products. The company provides products such as anacal ointment; dermacort cream; dipentum; gygel, a spermicidal contraceptive, and among others. Atnahs …
  • Viettel Group:企業の戦略・SWOT・財務情報
    Viettel Group - Strategy, SWOT and Corporate Finance Report Summary Viettel Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Regeneron Pharmaceuticals Inc (REGN):企業の製品パイプライン分析
    Summary Regeneron Pharmaceuticals Inc (Regeneron) discovers, develops, manufactures, and markets medicines for the treatment of serious medical conditions. Its marketed and pipeline products are focused on helping patients suffering with eye diseases, cancer, allergic and inflammatory diseases, meta …
  • The Empire District Electric Co:電力:M&Aディール及び事業提携情報
    Summary The Empire District Electric Co (EDE), a subsidiary of Liberty Utilities Co, is a regulated utility that provides electricity, natural gas, and water services. The company generates, procures, transmits, distributes, and sells electricity. It generates electricity from natural gas, coal, and …
  • Cairn India Ltd (CAIRN)-石油・ガス分野:企業M&A・提携分析
    Summary Cairn India Limited (Cairn India) is an independent oil and gas company. It explores for, develops, and produces oil and natural gas. The company has varying working interests in India, Sri Lanka and South Africa. Its blocks are located in the basins of Barmer, Krishna- Godavari, the Palar-P …
  • Brookfield Property REIT Inc (BPYU):企業の財務・戦略的SWOT分析
    Brookfield Property REIT Inc (BPYU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Clinigen Group Plc (CLIN):企業の財務・戦略的SWOT分析
    Summary Clinigen Group Plc (Clinigen Group) operates as a pharmaceutical and services company that provides access to clinical trials, medicines, unlicensed and commercial supply. The company acquires and licenses essential commercial medicines such as foscavir, cardioxane, ethyol, savene and vibati …
  • Australia and New Zealand Banking Group Ltd:企業の戦略・SWOT・財務情報
    Australia and New Zealand Banking Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Australia and New Zealand Banking Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • China Vanke Co., Ltd.:企業のM&A・事業提携・投資動向
    China Vanke Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Vanke Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Complexa Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Complexa Inc (Complexa) is a biopharmaceutical company that develops endogenous human cell signalling treatments for fibrosis and inflammation related diseases. The company’s lead product candidate products includes CXA-10 is an endogenous nitro fatty acid that modulates the human body’s mai …
  • Luxoft Holding Inc:企業の戦略・SWOT・財務分析
    Luxoft Holding Inc - Strategy, SWOT and Corporate Finance Report Summary Luxoft Holding Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Neurodyn Life Sciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Neurodyn Life Sciences Inc (Neurodyn Life Sciences), formerly Neurodyn Inc is a provider of validation and development of bioactives for neuroprotection and early treatment of neurological diseases. The company's products include neuroprotectant, memogain, progranulin, and nerve pain treatme …
  • U.S. Energy Corp (USEG):企業の財務・戦略的SWOT分析
    Summary U.S. Energy Corp (US Energy) is an oil and gas company that offers exploration, development and production of oil and natural gas properties. The company provides maintenance of mineral properties. It operates its oil and gas prospects located in the Williston Basin of North Dakota, the Eagl …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆